RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
Respiratory syncytial virus (RSV) causes infections of the lower respiratory tract. A group particularly vulnerable to severe infection are young children under 2 years of age and the elderly. The infection can cause the entire spectrum of respiratory symptoms from upper respiratory tract infections...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Kazimierz Wielki University,
2024-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_f9bd3d79a1ad43e69d6671e352d15ac6 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Paulina Dąbrowska |e author |
| 700 | 1 | 0 | |a Michał Żuber |e author |
| 700 | 1 | 0 | |a Karol Bochyński |e author |
| 700 | 1 | 0 | |a Katarzyna Molenda |e author |
| 700 | 1 | 0 | |a Katarzyna Ciuba |e author |
| 700 | 1 | 0 | |a Barbara Borodziuk |e author |
| 700 | 1 | 0 | |a Filip Borodziuk |e author |
| 700 | 1 | 0 | |a Michał Dacka |e author |
| 700 | 1 | 0 | |a Kamila Giżewska |e author |
| 700 | 1 | 0 | |a Konrad Białogłowski |e author |
| 245 | 0 | 0 | |a RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review |
| 260 | |b Kazimierz Wielki University, |c 2024-02-01T00:00:00Z. | ||
| 500 | |a 10.12775/JEHS.2024.61.003 | ||
| 500 | |a 2391-8306 | ||
| 520 | |a Respiratory syncytial virus (RSV) causes infections of the lower respiratory tract. A group particularly vulnerable to severe infection are young children under 2 years of age and the elderly. The infection can cause the entire spectrum of respiratory symptoms from upper respiratory tract infections to severe courses requiring assisted breathing. Until recently, the only form of protection against infection was passive immunization, i.e. administration of immunoglobulins. Chief among these are palivizumab and nirsevimab. In May u June 2023, the Food and Drug Administration (FDA) approved for use 2 vaccines against RSV are Arexvy and Abrysvo. In this study, we focus on presenting and describing the clinical evidence supporting the effectiveness of these immunization methods. | ||
| 546 | |a EN | ||
| 546 | |a ES | ||
| 546 | |a PL | ||
| 546 | |a RU | ||
| 546 | |a UK | ||
| 690 | |a Respiratory syncytial virus (RSV) | ||
| 690 | |a Bronchitis | ||
| 690 | |a RSV prevention | ||
| 690 | |a Palivizumab | ||
| 690 | |a Nirsevimab | ||
| 690 | |a RSV vaccine | ||
| 690 | |a Education | ||
| 690 | |a L | ||
| 690 | |a Sports | ||
| 690 | |a GV557-1198.995 | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Education, Health and Sport, Vol 61 (2024) | |
| 787 | 0 | |n https://apcz.umk.pl/JEHS/article/view/48320 | |
| 787 | 0 | |n https://doaj.org/toc/2391-8306 | |
| 856 | 4 | 1 | |u https://doaj.org/article/f9bd3d79a1ad43e69d6671e352d15ac6 |z Connect to this object online. |